

# IQVIA Longitudinal Patient Data - Belgium

**First published:** 01/02/2024

**Last updated:** 25/04/2025

Data source

Human

Primary care medical records

## Administrative details

### Administrative details

#### PURI

<https://redirect.ema.europa.eu/resource/1111116>

#### Data source ID

1111116

#### Data source acronym

LPD BE

#### Data holder

[IQVIA](#)

#### Data source type

Primary care medical records

## Main financial support

Funding by own institution

Funding from industry or contract research

---

## Care setting

Primary care – GP, community pharmacist level

---

## Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

---

## Data source website

<https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights>

## Contact details

Mui Van Zandt

Main

[mui.vanzandt@iqvia.com](mailto:mui.vanzandt@iqvia.com)

Hugo Vernooij

Alternate

[hugo.vernooi@iqvia.com](mailto:hugo.vernooi@iqvia.com)

## Data source regions and languages

## Data source countries

Belgium

---

## Data source languages

French

## Data source establishment

### Data source established

15/06/2005

---

### Data source time span

**First collection:** 01/01/2012

The date when data started to be collected or extracted.

## Publications

### Data source publications

[DARWIN EU® - Drug utilisation of valproate-containing medicinal products in women of childbearing potential](#)

## Studies

### List of studies that have been conducted using the data source

[Drug Utilisation Study of conjugated oestrogens/bazedoxifene \(CE/BZA\) in the European Union \(EU\)](#)

[Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study](#)

Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)

DARWIN EU® Prevalence of rare blood cancers in Europe

DARWIN EU® Drug utilisation of valproate-containing medicinal products in women of childbearing potential

DARWIN EU® Use of take-home naloxone for opioid overdose treatment

DARWIN EU® Drug utilization study of prescription opioids

DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis

DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages

DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis

DARWIN EU® - Drug utilisation study on medicinal use of *Pelargonii radix*

DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists

DARWIN EU® - Antipsychotic prescribing in the general population in Europe: a descriptive analysis of trends and patient characteristics

DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics

DARWIN EU® – Incidence rates of venous thromboembolic events in patients with selected cancers

DARWIN EU® - Impact of risk minimisation measures related to the risk of meningioma in women using nomegestrol and chlormadinone

DARWIN EU® – Monitoring prescription of medicines for public health emergencies at risk of shortages

DARWIN EU® Drug Utilisation Study of prescription opioids

## Data elements collected

### The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

---

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

---

#### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

No

---

#### **Hospital admission and/or discharge**

No

---

## ICU admission

Is information on intensive care unit admission available?

No

---

## Cause of death

Captured

---

## Cause of death vocabulary

Not coded (Free text)

---

## Prescriptions of medicines

Captured

---

## Prescriptions vocabulary

other

RxNorm

---

## Prescriptions vocabulary, other

CVX

---

## Dispensing of medicines

Captured

---

## Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

---

## Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

---

### **Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

---

### **Indication vocabulary**

Other

---

### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

---

### **Administration of vaccines**

No

---

### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

---

### **Procedures vocabulary**

SNOMED CT

---

### **Healthcare provider**

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?

The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

---

## Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

---

## Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

---

## Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

---

## Biomarker data vocabulary

Other

---

## Biomarker vocabulary, other

LOINC, SNOMED

---

## Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

---

## Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

---

## Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use

of services for the purpose of preventing or curing health problems.

Yes

---

### **Unique identifier for persons**

Are patients uniquely identified in the data source?

Yes

---

### **Diagnostic codes**

Captured

---

### **Diagnosis / medical event vocabulary**

SNOMED CT

---

### **Medicinal product information**

Captured

---

### **Medicinal product information collected**

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

---

### **Medicinal product vocabulary**

Other

RxNorm

---

### **If 'other,' what vocabulary is used?**

CVX

---

## **Quality of life measurements**

Captured

---

## **Quality of life measurements vocabulary**

Not coded (Free text)

---

## **Lifestyle factors**

Captured

---

## **Lifestyle factors**

Alcohol use

Tobacco use

---

## **Sociodemographic information**

Captured

---

## **Sociodemographic information collected**

Gender

Pharmaceutical copayment

## Quantitative descriptors

## Population Qualitative Data

### **Population age groups**

Paediatric Population (< 18 years)

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days - 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly ( $\geq$  65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

**Estimated percentage of the population covered by the data source in the catchment area**

300 GPs

Total DB: ~17M+ prescription orders written

Active patients: ~3% of the national population

---

**Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)**

Generell Population

## Family linkage

**Family linkage available in the data source permanently or can be created on an ad hoc basis**

Ad hoc

## Population

**Population size**

1131350

**Active population size**

408924

Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	184110	58163
Infants and toddlers (28 days - 23 months)	15556	4106
Children (2 to < 12 years)	103753	31844
Adolescents (12 to < 18 years)	64801	22213
Adults (18 to < 46 years)	419882	140413
Adults (46 to < 65 years)	274695	108548
Elderly (≥ 65 years)	252663	101800
Adults (65 to < 75 years)	113530	49156
Adults (75 to < 85 years)	82368	33396
Adults (85 years and over)	56765	19248

Median observation time

**Median time (years) between first and last available records for unique individuals captured in the data source**

0.30

---

**Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt**

6.20

## Data flows and management

### Access and validation

#### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

#### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

---

#### **Access to subject details**

Can individual patients/practitioners/practices included in the data source be contacted?

No

---

## **Description of data collection**

Anonymized patient records collected from patient management software used by GPs to document patients' clinical records

## Event triggering registration

### **Event triggering registration of a person in the data source**

Practice registration

---

### **Event triggering de-registration of a person in the data source**

Loss to follow up

Other

Practice deregistration

---

### **Event triggering de-registration of a person in the data source, other**

Emigration

---

### **Event triggering creation of a record in the data source**

Physician encounter

## Data source linkage

### **Linkage**

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

Yes

## Linked data sources

**Pre linked**

Is the data source described created by the linkage of other data sources?

No

---

**Data source, other**

Ad hoc data collected prospectively

## Data management specifications that apply for the data source

**Data source refresh**

Quarterly

---

**Informed consent for use of data for research**

Not Required

---

**Possibility of data validation**

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

---

**Data source preservation**

Are records preserved in the data source indefinitely?

Yes

---

**Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

---

## Data source last refresh

15/09/2024

# Common Data Model (CDM) mapping

## CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

## CDM Mappings

### CDM name

OMOP

---

### CDM website

<https://www.ohdsi.org/Data-standardization/>

---

### Data source ETL CDM version

3.5.1

---

### Data source ETL frequency

3,00 months

---

### Data source ETL status

Completed